胸膜间皮瘤
Pleural mesothelioma
定义 英文原文（暂无中文）
A rare, aggressive respiratory tumor arising from mesothelial cells of the pleura characterized by chest pain, dyspnea, cough and fatigue. It is strongly associated with asbestos exposure and typically develops after a long latency period (20-40 years). It usually presents as a diffuse invasive tumor but may also occur as a localized mass or as pleural mesothelioma in situ, a preinvasive lesion confined to the pleural surface.
基本事实
- 遗传方式
- 多基因/多因素
- 发病年龄
- 各年龄段
- 患病率
- 1-9 / 100 000（Europe）
相关基因 1
| 基因 | 名称 | 关联类型 |
|---|---|---|
| BAP1 | BRCA1 associated deubiquitinase 1 | Disease-causing germline mutation(s) in |
临床表型 17
极常见 99–80%1
- 胸腔积液 HP:0002202
常见 79–30%8
- 胸廓形态异常 HP:0000765
- 胸膜异常 HP:0002103
- 胸痛 HP:0100749
- 全身性症状 HP:0025142
- 咳嗽 HP:0012735
- 呼吸困难 HP:0002094
- 呼吸窘迫 HP:0002098
- 体重减轻 HP:0001824
偶见 29–5%8
- 肺部形态异常 HP:0002088
- 呼吸系统生理异常 HP:0002795
- 心血管系统生理异常 HP:0011025
- 吞咽困难 HP:0002015
- 第四组颅神经麻痹 HP:0007011
- 肝脏肿大 HP:0002240
- 淋巴结肿大 HP:0002716
- 上腔静脉梗阻 HP:0031041
近两年的全球研究 2,032L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-08Insights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines
- 2026-07Successful Diagnostic Confirmation of Malignant Pleural Mesothelioma With Extensive Pleural Adhesions Using Pleural Cryobiopsy Under Local Anaesthesia
- 2026-07Low baseline cGAS expression is associated with longer progression-free survival in patients with pleural mesothelioma
- 2026-07ASO Visual Abstract: Treatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication
- 2026-07Efficacy of Perioperative Platinum-Pemetrexed Chemotherapy Combined with Pleurectomy/Decortication for Pleural Mesothelioma
- 2026-07Brief report: attitudes and barriers toward genetic testing in pleural mesothelioma: a nationwide Italian survey
- 2026-07Epidemiological and Prognostic Differences in Malignant Mesothelioma Between Eastern China and SEER Database
- 2026-07Treatment for Oligo-recurrence of Diffuse Pleural Mesothelioma After Extended Pleurectomy/Decortication
- 2026-07Epiproteomic profiling identifies histone H4 hyperacetylation as a prognostic marker in pleural mesothelioma
- 2026-07Maintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study
- 2026-07综述Optimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies
- 2026-07综述Intratumour, anatomical and temporal heterogeneity in mesothelioma
- 2026-07Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer
- 2026-07综述Involvement of lysosomal proteins in morphology-driven toxicity of (nano)fibers
- 2026-07Glycan Fingerprint of Malignant Pleural Mesothelioma
- 2026-07Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
- 2026-07AI-assisted Volumetric Response Assessment in Pleural Mesothelioma
- 2026-07综述Immunohistochemical Loss of MTAP as a Diagnostic and Prognostic Surrogate of <i>CDKN2A/B</i> Homozygous Deletion: A Narrative Review
- 2026-07Correction to "Effects of Autophagy Inhibition by SAR405, a Selective VPS34 Inhibitor, on Pleural Mesothelioma Cells"
- 2026-07综述Interventional Radiology and Thoracic Oncology: 20 Years of Innovation
境外已获批用于本病的药物 2L2
欧盟 1 项、美国 1 项。同一药物在两地各批一次的，会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径，各有各的条件与费用。这一节能确定地告诉你的只有一件事：这个病在世界范围内已经有获得批准的药物，它叫什么名字。拿这个名字去问主治医生，是下一步最省力的做法。
药名一律保留英文原文，不作翻译——中国的药品通用名与英文名的音译经常不一致，译错会让人去找一个不存在的药。
已获孤儿药资格、尚未获批的在研药物（1 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- Arenegyr美国2008-08-22Treatment of malignant pleural mesothelioma官方记录
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
在中国开展的临床试验 20L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实，并与主治医生商量。
登记为可入组 8
- 招募中NCT03917043APG-2449 in Patients With Advanced Solid Tumors中国研究中心 9 个：Beijing、Changsha、Fuzhou、Guangzhou、Hangzhou、Wuhan 等 7 地
- 招募中NCT06726564A Study of MT027 in Patients with Pleural Malignant Tumors中国研究中心 1 个：Beijing
- 招募中NCT06535607Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors中国研究中心 25 个：Anyang、Beijing、Bengbu、Changchun、Changsha、Chengdu 等 25 地
- 招募中NCT05188859First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma中国研究中心 2 个：Beijing、Taiyuan
- 招募中NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors中国研究中心 4 个：Beijing、Guangzhou、Shanghai、Zhengzhou
- 招募中NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma中国研究中心 1 个：Changchun
- 尚未开始招募NCT07282873Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors中国研究中心 1 个：Shanghai
- 招募中NCT07510815Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma中国研究中心 1 个：Shenzhen
其他状态的试验（12 项）
- 状态未知NCT02580747Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso中国研究中心 1 个：Beijing
- 已完成NCT02899299Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients中国研究中心 5 个：Changchun、Harbin、Kunming、Shanghai、Shenyang
- 已终止NCT03393858Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma中国研究中心 1 个：Beijing
- 状态未知NCT03852823Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours中国研究中心 1 个：Shanghai
- 状态未知NCT05042557Real World Study of MPM in China中国研究中心 1 个：Beijing
- 已完成NCT05136677A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants中国研究中心 21 个：Beijing、Changchun、Changsha、Chengdu、Hangzhou、Harbin 等 17 地
- 状态未知NCT05598268A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.中国研究中心 7 个：Beijing、Bengbu、Chengdu、Guanzhou、Luoyang、Shanghai 等 7 地
- 状态未知NCT05498597AMT-151 in Patients With Selected Advanced Solid Tumours中国研究中心 3 个：Changsha、Fuzhou、Shanghai
- 状态未知NCT06031636Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma中国研究中心 1 个：Tianjin
- 状态未知NCT05930665Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma中国研究中心 1 个：Guangzhou
- 进行中·不再招募NCT06097728MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma中国研究中心 18 个：Beijing、Changsha、Chengdu、Guangzhou、Hangzhou、Harbin 等 18 地
- 状态未知NCT06256055Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors中国研究中心 1 个：Beijing
中国境外的在招试验 59L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
美国26意大利8法国5英国5澳大利亚2比利时2荷兰2韩国2西班牙2丹麦1埃及1德国1希腊1加拿大1另有 3 个国家/地区
CT.gov 报告命中 59 项，此处取回并展示最近的 15 项。
- 尚未开始招募NCT07713732TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors澳大利亚
- 招募中NCT06971848Evaluation of Skin Tests in Biotherapy Allergies法国
- 招募中NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease美国
- 招募中NCT07443020Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors美国
- 招募中NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer美国
- 招募中NCT07234058Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma法国
- 尚未开始招募NCT07550049Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology
- 招募中NCT07277413A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors美国
- 招募中NCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma美国
- 尚未开始招募NCT07131345Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
- 招募中NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study比利时
- 招募中NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy法国
- 尚未开始招募NCT05425576OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition美国
- 招募中NCT06756035CT-95 in Advanced Cancers Associated With Mesothelin Expression美国
- 招募中NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma丹麦
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）